Vaxart appoints Steven Lo as CEO and President; Finney remains Chair

Vaxart, Inc.

Steven Lo appointed CEO, President, and director effective March 18, 2024.
Michael Finney steps down as interim CEO but continues as Board Chair.
Lo receives base salary of $600,000/year and target bonus of 50% of salary.
Equity awards: option for 1,000,000 shares (4-year vest) and RSU for 250,000 shares (4-year vest).
Lo brings 25+ years biopharma experience, most recently CEO at Valitor.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael J. Finney

Interim President and Chief Executive Officer

VXRT · Vaxart, Inc.

Effective: 2024-03-18
Successor: Steven Lo
Filed: March 6, 2024, 6:59 PM ET

In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.

Appointed

Steven Lo

Chief Executive Officer, President, and director

VXRT · Vaxart, Inc.

Effective: 2024-03-18
Filed: March 6, 2024, 6:59 PM ET

On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael J. Finney changed role as Interim President and Chief Executive Officer at Vaxart, Inc..

Action: stepped down
Role: Interim President and Chief Executive Officer

Exact text from the filing

In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven Lo was appointed as Chief Executive Officer, President, and director at Vaxart, Inc..

Action: appointed
Role: Chief Executive Officer, President, and director

Exact text from the filing

On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).

View on SEC.gov

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-006743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.